Skip to content

    Neuland Labs.

    NEULANDLABGood
    Healthcare·7 Nov 2025
    Management Summary

    Neuland Labs delivered a record-breaking performance in Q2 FY26, with revenue and profitability soaring due to strong execution in its commercial CMS business. The impressive top-line growth of 63.7% and an EBITDA margin of 30.4% highlight significant operating leverage. However, this rapid growth strained working capital, leading to higher inventory, increased receivables, and negative cash flow. Management remains confident in the full-year outlook, emphasizing the long-term potential of its peptide facility investments and a strengthening project pipeline, while cautioning investors about the inherent quarter-to-quarter volatility of the business.

    Highlights

    8

    • Total Income surged to ₹516 crores, a 63.7% YoY increase from ₹315 crores in Q2FY25.

    • EBITDA stood at ₹156.9 crores, with a robust EBITDA margin of 30.4%.

    • Profit After Tax (PAT) grew significantly to ₹96.5 crores, compared to ₹32 crores in the same period last year.

    • Earnings Per Share (EPS) for the quarter was ₹75.18.

    • Gross Margin improved to 60.1% from 56.3% in Q2FY25, driven by a favorable business mix tilting towards CMS.

    • Growth was primarily driven by the strong performance of the top two commercial CMS molecules.

    • Working capital deteriorated, with working capital days at 155 and a negative pre-cash flow of ₹141 crores for the quarter.

    • Management reiterated its expectation for a year of strong growth in FY26.

    Concerns

    1

    • Working Capital Deterioration & Negative Cash Flow

    What Changed3

    vs Q3 FY26

    Tone shiftMixed → GoodGuidance items5 → 4 (-1)Risks discussed4 → 3 (-1)

    Key financials

    Single quarter

    06 metrics
    1. 01Total Income₹516 Cr+63.7%YoY
    2. 02EBITDA₹156.9 Cr
    3. 03EBITDA Margin30.4%
    4. 04Gross Margin60.1%
    5. 05PAT₹96.5 Cr+2.0%YoY

    Guidance & targets

    4
    CategoryTargetPriority
    Growth
    Full Year Growth
    Strong growth on a base of FY24
    		High
    Pipeline
    New Molecule Commercialization
    Commercialization of one new molecule
    		High
    Capex
    Peptide Facility Completion
    New peptide facility to be completed
    		High
    Capex
    Peptide Facility Investment (Module 1 & 2)
    ₹250-280 crores
    		High

    Risks & concerns

    5
    RiskSeverity

    Working Capital Deterioration & Negative Cash Flow

    Management confirmed deterioration due to higher inventories and receivables, leading to a negative pre-cash flow of ₹141 crores. They are actively working on optimization. — Management acknowledged

    high

    Business Lumpiness and Quarter-on-Quarter Volatility

    Management repeatedly cautioned that the CDMO business is inherently uneven and should be evaluated on an annual basis, not quarterly. — Management acknowledged

    medium

    External Factors

    Risks include customer R&D failures, FX fluctuations, raw material cost volatility, and geopolitical issues. — Management acknowledged

    medium

    Areas of Evasion(2)

    • Product-specific details (utilization, pricing)
    • Specific quantitative capacity of peptide facility

    Q&A highlights

    3

    “So, unfortunately, I think it's very difficult to answer what the capacity of this facility would be in terms of kilos or tons of peptide. But the largest reactor we plan to have is 2,000-liter SPPS.”

    Management avoided giving a specific capacity number for the highly anticipated peptide/GLP-1 space, highlighting that output is process-dependent, which makes it difficult for investors to model the potential revenue contribution.

    asked by Amey

    2 min read5 chapters

    Detailed Narrative

    01

    Record Q2 Performance Driven by Commercial CMS

    Neuland Labs reported its best-ever quarter, with total income reaching ₹516 crores, a 63.7% YoY growth. This surge was primarily driven by strong performance from its top two commercial CMS molecules. The favorable business mix and operating leverage resulted in a robust EBITDA margin of 30.4% and a PAT of ₹96.5 crores. Management highlighted that this performance is an indicator of the strong growth trajectory expected for the full financial year FY26.

    02

    Working Capital Under Strain Amidst High Growth

    The rapid growth in Q2 led to a significant strain on working capital. Management acknowledged a deterioration over the last two quarters, with working capital at 155 days of sales. This was caused by higher inventories built up for future orders and uneven order flow leading to higher receivables. Consequently, the pre-cash flow for the quarter was negative at ₹141 crores. The company is now focused on inventory optimization and achieving a more even delivery flow to improve the cash position.

    03

    Strategic Investment in Peptide Manufacturing Deepens

    The company is moving forward with its strategic investment in a large-scale, four-module peptide facility. Management confirmed that Module-1 will be fully operational by the next financial year, with civil work for Module-2 also underway. The initial investment for this phase is estimated to be between ₹250-280 crores. This facility is crucial for attracting large-scale commercial peptide projects, a key long-term growth driver for the company.

    04

    GDS Business Shows Mixed Performance

    The Generic Drug Substances (GDS) business had a mixed quarter. The prime products segment, including Ezetimibe and Mirtazapine, delivered good contributions. However, the GDS specialty segment was described as 'subdued', with contributions from sterile products like Paliperidone and Aripiprazole. This indicates that while the CMS business is firing on all cylinders, the GDS segment's growth is less uniform.

    05

    Outlook: Confident on FY26 Growth but Cautious on Volatility

    Management reiterated its confidence that FY26 will be a year of 'strong growth' compared to the FY24 baseline. This is supported by the expected commercialization of another CMS molecule this year and a strong pipeline of new business with deliveries scheduled over the next 12-18 months. However, they repeatedly cautioned investors about the 'inherent uneven nature' and 'lumpiness' of the CDMO business, advising a long-term, annual perspective rather than focusing on quarter-on-quarter fluctuations.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.